The current paradigm for managing MM involves the use of triplet regimens that incorporate an anti-CD38 monoclonal antibody and dexamethasone along with a proteasome inhibitor (PI) and/or an immunomodulatory drug (IMiD) (12). Here, CD38 is linked to Miyoshi myopathy.